Baird, Wells Fargo Downgrade Inspire Medical Systems Amid Physician Reimbursement Concerns

Inspire Medical Systems (INSP) has faced significant analyst downgrades from Baird and Wells Fargo. The firms cited growing uncertainties surrounding potential changes to physician reimbursement policies as a primary driver. Specifically, modifications to coding for Inspire V could lead to a substantial reduction in physician payments, estimated between 10% and 50%. This outlook, coupled with a lowered growth forecast for 2026, has prompted a more cautious stance from analysts. Such reductions could negatively impact future utilization rates and the company's ability to drive new account growth. Despite the company recently exceeding Q4 revenue expectations, these fundamental concerns are weighing heavily on investor sentiment. The downgrades underscore potential headwinds for INSP in the near to medium term.